WO2018016631A1 - 皮脂量増加剤およびヒアルロン酸産生促進剤 - Google Patents
皮脂量増加剤およびヒアルロン酸産生促進剤 Download PDFInfo
- Publication number
- WO2018016631A1 WO2018016631A1 PCT/JP2017/026502 JP2017026502W WO2018016631A1 WO 2018016631 A1 WO2018016631 A1 WO 2018016631A1 JP 2017026502 W JP2017026502 W JP 2017026502W WO 2018016631 A1 WO2018016631 A1 WO 2018016631A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- acid production
- increasing agent
- production promoter
- hot water
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/985—Skin or skin outgrowth, e.g. hair, nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to a sebum amount increasing agent and a hyaluronic acid production promoting agent, which contains ash as an active ingredient.
- the skin is an organ located in the outermost outline of the living body, and has important physiological functions such as biological defense, sense, temperature regulation and excretion. Such functions are regulated not only by the epidermis and fibroblasts, which are the main components of the skin, but also by skin appendages such as sebaceous glands (sebaceous glands). That is, it is considered essential for the construction of structural and functional barriers of the skin that the functions of the epidermis, dermis and sebaceous gland are regulated and maintained in an integrated manner.
- the main component of sebum secreted from sebaceous glands is triacylglycerol synthesized in sebaceous cells, and also contains lipids specific to sebaceous glands such as wax esters and squalene.
- Sebum excreted from the sebaceous gland maintains the skin's homeostasis by suppressing moisture transpiration from the skin, and maintains the epidermis at a low pH due to the presence of free fatty acids generated by the decomposition of triacylglycerol in the sebum
- Weakly acidic lipid membranes also play a buffering action against harmful substances and a biological defense function. Therefore, if the sebum synthesis and production is insufficient, the biological defense mechanism cannot function sufficiently, and it may induce alleviation of allergic symptoms.
- Patent Document 1 describes an invention relating to a sebum production promoter characterized by using a germinated broccoli-derived component as an active ingredient.
- Hyaluronic acid is a type of glycosaminoglycan that forms an extracellular matrix together with proteins such as collagen and elastin. Hyaluronic acid is considered to contribute to the moisture retention of the skin because of its excellent water retention.
- Hyaluronic acid has glucuronic acid and N-acetylglucosamine as structural units, synthesized in vivo by hyaluronic acid synthase (HAS), and degraded by degrading enzymes such as hyaluronidase.
- HAS hyaluronic acid synthase
- degrading enzymes such as hyaluronidase.
- Patent Document 2 describes an invention relating to a hyaluronic acid production promoter of a collagen peptide.
- the present invention has been made in view of the above circumstances, and an object thereof is to provide a highly active sebum amount increasing agent and hyaluronic acid production promoter containing an active ingredient derived from a natural product.
- FIG. 1 shows hamsters cultured for 6 days after treatment every 3 days in a medium containing Ag (vacuum), spray glue, fish-derived peptide (peptide FPC), porcine-derived peptide (PRA-PC) or denatured collagen (gelatin) It shows the amount of intracellular triacylglycerol (TG) in sebocytes (in the figure, “**” (p ⁇ 0.01) and “***” (p ⁇ 0.001) are the control group (Cont)). To be statistically significant.)
- FIG. 2 is an oil red O-stained image of hamster sebaceous cells cultured for 6 days after treatment every 3 days in a medium containing insulin (positive control), glue (vacuum) or spray glue.
- FIG. 1 shows hamsters cultured for 6 days after treatment every 3 days in a medium containing Ag (vacuum), spray glue, fish-derived peptide (peptide FPC), porcine-derived peptide (PRA-PC) or denatured collagen (gelatin) It shows
- FIG. 3 shows the amount of hyaluronic acid (HA) in the medium after culturing human epidermis cells for 24 hours in a medium containing Ag (vacuum) or spray glue (in the figure, “*” (p ⁇ 0.05)).
- HA hyaluronic acid
- FIG. 4 shows the relative expression level of hyaluronan synthase-2 (HAS-2) mRNA in human epidermal cells cultured for 24 hours in a medium containing vacuum (vacuum) or spray glue (“*” ( p ⁇ 0.05) is significant relative to the control group (Cont) and “##” (p ⁇ 0.01) is statistically significant to IL-1 ⁇ treated cells .)
- FIG. 5 shows the amount of hyaluronic acid (HA) in fresh medium supplemented with Ag (vacuum) or spray glue (FIG. 5A), and in medium supplemented with spray glue pretreated in the presence or absence of hyaluronidase. The amount of hyaluronic acid (HA) (FIG. 5B) is shown.
- FIG. 6 shows the relative expression level of HAS-2 mRNA in human epidermal cells cultured for 24 hours in a medium containing spray glue pretreated in the presence or absence of hyaluronidase (in the figure, “*” (p ⁇ 0.05) and “**” (p ⁇ 0.01) indicate statistical significance relative to the control group (Cont).
- FIG. 7 shows hyaluronic acid (HA) in a medium after culturing human epidermal cells in a medium containing spray glue for 24 hours, irradiating with ultraviolet rays (UVB, 0.6 kJ / m 2 ), and further culturing for 24 hours. The amount is shown (in the figure, “***” (p ⁇ 0.001) is statistically significant with respect to non-UV irradiation (None), and “##” (p ⁇ 0.001) Indicates statistical significance relative to the control group (Cont).
- X to Y indicating a range means “X or more and Y or less”. Unless otherwise specified, measurements such as operation and physical properties are performed under conditions of room temperature (20 to 25 ° C.) / Relative humidity 40 to 50% RH.
- One embodiment of the present invention is a sebum amount increasing agent containing a glue as an active ingredient. Another aspect of the form relates to the use of glue in the manufacture of sebum increasing agents. A further aspect of the form relates to glue for increasing the amount of sebum.
- Another embodiment of the present invention is a hyaluronic acid production promoter containing a glue as an active ingredient.
- Another aspect of the form relates to the use of glue in the production of a hyaluronic acid production promoter.
- a further aspect of the form relates to glue for promoting hyaluronic acid production.
- a highly active sebum amount increasing agent and hyaluronic acid production promoter containing an active ingredient derived from a natural product can be provided.
- Aji is a herbal medicine listed in the Japanese Pharmacopoeia Standards for Herbal Medicine, and is an extract of the skin of the equine animal, donkey (Equus asinus L.). Agoa is said to have effects such as supplementation and hemostasis, and its use is considered as an active ingredient in whitening cosmetics.
- “Aji” includes purified products obtained by further purifying a hot water extract (decoction) of donkey skin, processed products such as enzyme-treated products treated with any degrading enzyme, etc. As long as the desired effect is obtained.
- the glue contained as an active ingredient in the hyaluronic acid production promoter is a hyaluronidase-treated product.
- a hyaluronidase-treated product of Ag an extract obtained from donkey skin by the method described later is used in an optional solvent at an optional concentration, for example, 0.01 to 1000 mg / ml, preferably 0.5 to It is obtained by dissolving to 50 mg / ml and enzymatically degrading hyaluronic acid with hyaluronidase.
- a solvent water, a buffer solution such as a phosphate buffer solution having a pH of about 5 to 8, an acetate buffer solution, a good buffer such as HEPES, or a physiological saline solution may be used.
- the amount of hyaluronidase added can be arbitrarily adjusted depending on the amount of the extract, and is, for example, a concentration of 10 to 1000 RTU / ml.
- the reaction temperature and time for the hyaluronidase treatment are not particularly limited, but for example, it is 30 to 45 ° C. for about 1 to 100 hours, preferably 10 to 30 hours. After the reaction, the enzyme is preferably deactivated by heating or the like.
- the mixture can be pulverized and dried by means described later to obtain a glue as a hyaluronidase-treated product.
- the amount of hyaluronic acid contained in the treated product of hyaluronidase can be confirmed by a conventionally known method such as an ELISA method as described in Examples.
- containing as an active ingredient means containing to some extent effective as a sebum amount increasing agent or hyaluronic acid production promoter, and preventing inclusion of other components such as a pharmaceutically acceptable carrier. I can't.
- the method for producing the sebum amount increasing agent and hyaluronic acid production promoter according to the present invention is not particularly limited as long as the desired effect of the present invention is achieved.
- the preferable manufacturing method of a sebum amount increasing agent and a hyaluronic acid production promoter is demonstrated.
- the sebum amount increasing agent is preferably produced by a production method including obtaining a dried product of a hot water extract of donkey (Equus asinus L.) by vacuum drying. That is, in one embodiment of the present invention, a sebum amount increasing agent comprising obtaining a hot water extract of donkey skin (Equus asinus L.) and obtaining a dried product of the hot water extract by vacuum drying. A manufacturing method is provided.
- the sebum amount increasing agent manufactured by such a manufacturing method is particularly excellent in the effect of increasing the sebum amount.
- the hyaluronic acid production promoter is preferably produced by a production method including obtaining a dried product of a hot water extract of donkey skin (Equus asinus L.) by spray drying. That is, in another embodiment of the present invention, hyaluronic acid production comprising obtaining a hot water extract of donkey skin (Equus asinus L.) and obtaining a dried product of the hot water extract by spray drying A method for producing an accelerator is provided.
- the hyaluronic acid production promoter produced by such a production method is particularly excellent in hyaluronic acid production promoting effect.
- the conditions for hot water extraction in the production of the above-mentioned sebum amount increasing agent and hyaluronic acid production promoter are not particularly limited.
- the amount of heat is 3 to 10 ml, preferably 3 to 5 ml per 1 g of donkey skin.
- the extraction temperature (hot water temperature) is, for example, 70 to 100 ° C., preferably 90 to 100 ° C.
- the extraction time is not particularly limited, but is, for example, 5 to 12 hours, preferably 6 to 12 hours. Extraction may be performed multiple times.
- the extract prepared by such a method may be concentrated using a centrifugal concentrator as necessary.
- lower alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, tert-butanol, etc. are optionally added to the extract to increase the vapor pressure May be.
- additives for formulation such as conventionally known excipients may be optionally added to the hot water extract.
- filler For example, sugars and sugar alcohols, such as lactose, sucrose, glucose, a cellulose, a mannitol; Starches, such as wheat starch, potato starch, corn starch; Dextrins, such as cyclodextrin; Examples thereof include cellulose derivatives such as (CMC), hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose; and synthetic polymer compounds such as polyvinyl pyrrolidone.
- lipophilic ingredients such as olive oil, soybean oil, cottonseed oil, cacao butter, squalane, shellac, cetanol, polyoxyethylene hydrogenated castor oil, polyglycerin fatty acid ester, sucrose fatty acid ester, lecithin, and other additives for formulation May be added to the extract.
- the amount of the additive is, for example, 0.1 to 5% by weight with respect to the hot water extract.
- the hot water extract prepared as described above is preferably dried by the following method.
- the hot water extract is dried by vacuum drying.
- the vacuum drying conditions are, for example, 0.1 to 1 kPa, preferably 0.5 to 0.8 kPa.
- the drying temperature is, for example, 80 to 100 ° C., preferably 80 to 85 ° C.
- the drying time is, for example, a time when the water content is 4 to 8% by weight, preferably 4 to 6% by weight. Vacuum drying is particularly preferably used in the production of the sebum amount increasing agent.
- the hot water extract is dried by spray drying.
- the drying inlet temperature (intake air temperature) is, for example, 120 to 190 ° C., preferably 140 to 170 ° C.
- the drying outlet temperature (exhaust temperature) at the time of spray drying is, for example, 70 to 100 ° C., preferably 80 to 90 ° C.
- the water content after spray drying is, for example, 4 to 8% by weight, preferably 4 to 6% by weight.
- Spray drying is particularly preferably used in the production of a hyaluronic acid production promoter.
- the dried product may be optionally pulverized by known means such as a hammer mill, jet mill, pin mill, bead mill, mass collider, mixer, homogenizer and the like.
- the average particle size of the dried product (when pulverized, the average particle size after pulverization) is, for example, 120 to 2000 ⁇ m, preferably 180 to 1500 ⁇ m.
- the average particle diameter is a value measured by a particle size analyzer. A fraction having a desired particle diameter may be collected by a sieve or the like.
- the active ingredient, glue may be formulated together with other pharmaceutically acceptable ingredients.
- other pharmaceutically acceptable ingredients include, in addition to the above-mentioned excipients, carriers, diluents, extenders, emulsifiers, thickeners, disintegrants, solubilizers, stabilizers, preservatives, Examples include buffers, lubricants, binders, pH adjusters, ultraviolet absorbers, isotonic agents, antioxidants, preservatives, surfactants, colorants, fragrances, and sweeteners.
- the dosage form is not particularly limited, and can be formulated into any form of oral or parenteral, for example, tablet, pill, powder, granule, fine granule, solution, capsule, elixir, suspension Examples include liquids, emulsions, syrups, injections, external preparations (eg, ointments, creams, gels, sprays, patches, lotions, etc.), suppositories, and the like.
- the administration route is not particularly limited, and any administration route including oral administration, enteral nasal administration, transdermal administration, injection administration (for example, intravenous administration, subcutaneous administration, intramuscular administration, intraperitoneal administration, etc.) can be used. In addition, it may be in the form of a facial cleanser, shampoo, rinse, cosmetic or the like.
- the content of the active ingredient in the preparation is, for example, 0.01 to 90% by weight, preferably 1 to 10% by weight.
- the optimum dose of the sebum amount increasing agent and hyaluronic acid production promoter varies depending on the age, weight, sex, symptom, administration method, etc. of the patient, but for example, 0.1 ⁇ g to 1 kg / kg body weight in one administration It can be administered once to several times per day at a rate of 1000 mg, preferably 10 ⁇ g to 50 mg.
- the subject to which the sebum amount increasing agent and hyaluronic acid production promoter according to the present invention are administered may be any human or non-human animal, for example, human, monkey, mouse, rat, hamster, rabbit, guinea pig, Mammals including cattle, pigs, dogs, horses, cats, goats and sheep, and birds, preferably humans.
- ⁇ Production Example 2 Spray glue>
- the hot water extract sterilized by heating in the same manner as above is spray-dried (model name LPG-200, manufactured by Henan Shingo Co., Ltd., drying inlet temperature (intake air temperature) 150 ° C, drying outlet temperature (exhaust temperature) 85 ° C).
- the sample was dried to obtain a sample (spray glue) as a dried product having an average particle size of 500 ⁇ m and a water content of 4.5% by weight.
- the average particle size was measured with a particle size analyzer.
- Example 1 Sebum amount increasing agent> Using the samples prepared in Production Examples 1 and 2, the effect of increasing the amount of sebum was verified.
- SEB medium Dulbecco's modified Eagle medium / Ham F12 (1: 1 (v / v)) (Invitrogen), 6% (v / v) heat-denatured fetal calf serum (JRH bioscience), 2% (V / v) Human serum (ICN biochemicals, 0.68 mM L-glutamine (Invitrogen)) was added to the medium so that the final concentration of the sample was as described above, and the reaction was performed at 37 ° C. The cells were cultured in a CO 2 incubator (5% (v / v) CO 2 ).
- the cultured hamster sebaceous gland cells were stained with oil red O for neutral fat accumulated in the cells. As shown in FIG. 2, the number of cells positive for oil red O staining in hamster sebaceous gland cells treated with glue (vacuum) (0.5-5 mg / ml) and spray glue (0.5-5 mg / ml) Increased in a concentration-dependent manner.
- Example 2 Hyaluronic acid production promoter> Using the samples prepared in Production Examples 1 and 2, the hyaluronic acid production promoting effect was verified.
- the cells were irradiated with UVB (313 nm, Toshiba FL 20S fluorescent lamp, 0.6 kJ / m 2 ) and then cultured in the presence of spray glue (5 mg / ml) for 24 hours.
- UVB 313 nm
- Toshiba FL 20S fluorescent lamp 0.6 kJ / m 2
- RNA was extracted from the cells collected after the culture using ISOGEN (Nippon Gene Co., Ltd.). Using the obtained RNA as a sample, the expression level of hyaluronic acid synthase-2 (HAS-2) mRNA was measured by a quantitative PCR method (measuring instrument name: Thermal Cycler Dice TM Real Time System, Takara Bio Inc.). In addition, the measurement of mRNA by quantitative PCR method was performed using Prime Script RT reagent kit (Takara Bio Inc.), 2 x QuantTect SYBER Green PCR master Mix (Qiagen) as a measurement reagent. The expression level of HAS-2 mRNA was calculated as a relative value corrected by the expression level of the internal standard gene glyceraldehyde 3-phosphate dehydrogenase.
- HAS-2 hyaluronic acid synthase-2
- Ag is a hot water extract (decoction) of donkey skin and therefore contains hyaluronic acid.
- HA was also present in fresh medium in which Ag (vacuum) or spray Ag was dissolved (FIG. 5A).
- spray glue solution dissolved in 5 mg / ml, 50 mM acetic acid / 0.15 M NaCl (pH 6)
- hyaluronidase 100 RTU / ml
- Human epidermal cells were cultured for 24 hours in a medium containing the hyaluronidase treated product of spray glue prepared as described above.
- the expression level of HAS-2 mRNA in the cultured human epidermal cells was measured.
- the hyaluronidase-treated product also had an HAS-2 mRNA expression promoting action (FIG. 6).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
ロバの皮を水で洗浄した後に剃毛し、ロバの皮50gに対して200mlの熱水(95℃)中で8時間抽出した。熱水抽出は3回繰り返した。抽出液をフイルタでろ過した後、合一し、100mlの抽出液に対して0.2mlの0.4重量%エタノール水溶液、0.2gのショ糖、および0.2gの大豆油を添加し、遠心濃縮機にて2~3倍程度まで濃縮して、ロバの皮の熱水抽出物を得た。その後、95℃で30分間加熱殺菌した熱水抽出物を真空乾燥機(機種名BVD205、温州金榜社製、真空度0.6kPa、乾燥温度85℃)にて水分含量5.5重量%まで乾燥させた。乾燥物を粉砕機にて粒径1000μm以下に粉砕し、試料(阿膠(真空))とした。
上記と同様に加熱殺菌した熱水抽出物を、スプレードライ装置(機種名LPG-200、河南新郷社製、乾燥入口温度(吸気温度)150℃、乾燥出口温度(排気温度)85℃)にて乾燥し、平均粒径500μm、水分含量4.5重量%の乾燥物として、試料(スプレー阿膠)を得た。なお、平均粒径は粒度分析器にて測定した。
上記の製造例1および2で調製した試料を用いて、皮脂量増加効果を検証した。
ハムスター脂腺細胞を、阿膠(真空)(0.5~5mg/ml)、スプレー阿膠(0.5~5mg/ml)、インスリン(10nM、陽性対照)、魚由来ペプチド(ペプチドFPC、株式会社ニッピより購入)(0.5~5mg/ml)、ブタ由来ペプチド(PRA-PC、株式会社ニッピより購入)(0.5~5mg/ml)または変性コラーゲン(ゼラチン、BDバイオサイエンス社)(0.5~1mg/ml)の存在下で3日ごとに培地交換を行い、6日間培養した。なお、ハムスター脂腺細胞の培養は、J Invest Dermatol 2001: 117: 965-970.に記載の方法に従い、SEB培地(ダルベッコ改変イーグル培地/ハムF12(1:1(v/v))(インビトロジェン)、6%(v/v)熱変性ウシ胎児血清(JRHバイオサイエンス)、2%(v/v)ヒト血清(ICNバイオケミカルズ)、0.68mM L-グルタミン(インビトロジェン))を用い、試料の終濃度が上記となるように培地に添加し、37℃にて行った。なお、細胞の培養はCO2インキュベーター(5%(v/v)CO2)内で行った。
図1に示す通り、阿膠(真空)(0.5~5mg/ml)およびスプレー阿膠(0.5~5mg/ml)は、濃度依存的にTG合成を促進した。また、阿膠によるTG合成促進作用は、スプレー阿膠よりも阿膠(真空)の方が強かった。
上記の製造例1および2で調製した試料を用いて、ヒアルロン酸産生促進効果を検証した。
正常ヒト表皮角化細胞(新生児由来、クラボウ社)を24ウェルプレートにてコンフルエントまで培養後、阿膠(真空)(0.1~1mg/ml)またはスプレー阿膠(0.5~5mg/ml)の存在下で24時間培養した。なお、ヒト表皮細胞の培養には、HuMedia-KG2培地(クラボウ社)を用い、CO2インキュベーター(5%(v/v)CO2)内で37℃で行った。また、紫外線照射試験は、細胞にUVB(313nm、Toshiba FL 20S蛍光ランプ、0.6kJ/m2)を照射した後に、スプレー阿膠(5mg/ml)存在下で24時間培養した。
図3に示す通り、阿膠(真空)(0.1~1mg/ml)およびスプレー阿膠(0.5~5mg/ml)は、濃度依存的にHA産生を促進した。阿膠によるHA産生促進効果は、より生体に近いIL-1α(10ng/ml)存在下でも確認され、阿膠(真空)よりもスプレー阿膠の方がヒアルロン酸分泌量は多かった。また、図4に示す通り、スプレー阿膠により、ヒト表皮細胞におけるHAS-2 mRNAの発現が促進された。したがって、阿膠によるHA産生の促進の一因としては、HAS-2 mRNAの発現増加を介して行われると推測される。
Claims (5)
- 阿膠を有効成分として含む、皮脂量増加剤。
- ロバ(Equus asinus L.)の皮の熱水抽出物を得ること、および
真空乾燥により前記熱水抽出物の乾燥物を得ることを含む、皮脂量増加剤の製造方法。 - 阿膠を有効成分として含む、ヒアルロン酸産生促進剤。
- 前記阿膠が、ヒアルロニダーゼ処理物である、請求項3に記載のヒアルロン酸産生促進剤。
- ロバ(Equus asinus L.)の皮の熱水抽出物を得ること、および
スプレードライにより前記熱水抽出物の乾燥物を得ることを含む、ヒアルロン酸産生促進剤の製造方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780045326.8A CN109475580A (zh) | 2016-07-21 | 2017-07-21 | 皮脂量增加剂和透明质酸产生促进剂 |
JP2018528897A JP6996038B2 (ja) | 2016-07-21 | 2017-07-21 | 皮脂量増加剤およびヒアルロン酸産生促進剤 |
KR1020197001996A KR102523796B1 (ko) | 2016-07-21 | 2017-07-21 | 피지량 증가제 및 히알루론산 생산 촉진제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016143382 | 2016-07-21 | ||
JP2016-143382 | 2016-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018016631A1 true WO2018016631A1 (ja) | 2018-01-25 |
Family
ID=60992630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/026502 WO2018016631A1 (ja) | 2016-07-21 | 2017-07-21 | 皮脂量増加剤およびヒアルロン酸産生促進剤 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6996038B2 (ja) |
KR (1) | KR102523796B1 (ja) |
CN (1) | CN109475580A (ja) |
WO (1) | WO2018016631A1 (ja) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01207242A (ja) * | 1988-02-15 | 1989-08-21 | Tsumura & Co | 副作用軽減剤 |
JPH02300131A (ja) * | 1989-05-15 | 1990-12-12 | Tsumura & Co | 発癌抑制剤 |
JP2007001909A (ja) * | 2005-06-22 | 2007-01-11 | Kanebo Home Products Kk | 植物抽出物の選択方法 |
CN101099843A (zh) * | 2007-07-18 | 2008-01-09 | 广州中医药大学 | 一种延缓皮肤衰老的中药组合物 |
CN101214057A (zh) * | 2007-01-04 | 2008-07-09 | 肖社生 | 一种养颜护肤品 |
JP2014208697A (ja) * | 2001-10-31 | 2014-11-06 | 有限会社大長企画 | 動物用皮膚用剤 |
JP2015501647A (ja) * | 2011-12-29 | 2015-01-19 | シャンドン ドンア アジャオ カンパニー リミテッドShandongdong−E E−Jiao Co., Ltd. | 活性小分子阿膠混合物、並びに、その調製方法及び用途 |
JP2016536344A (ja) * | 2013-09-25 | 2016-11-24 | シャンドン ドンア アジャオ カンパニー リミテッドShandong Dong−E E−Jiao Co., Ltd. | 毛髪改質剤組成物の製造における阿膠又は阿膠の高付加価値加工製品の応用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1079148A (zh) * | 1992-05-27 | 1993-12-08 | 山东平阴阿胶厂 | 速溶阿胶制备工艺 |
CN1792246A (zh) * | 2005-12-23 | 2006-06-28 | 上海交大昂立股份有限公司 | 一种能改善缺铁性贫血和改善皮肤水份和油份的营养食品 |
JP5571280B2 (ja) | 2007-11-09 | 2014-08-13 | 株式会社コーセー | 皮脂産生促進剤 |
CN102526106B (zh) * | 2010-12-31 | 2014-06-18 | 山东东阿阿胶股份有限公司 | 一种阿胶原粉及其制备方法 |
JP2014210766A (ja) | 2013-04-05 | 2014-11-13 | 御木本製薬株式会社 | ヒアルロン酸産生促進剤、ヒアルロン酸合成酵素遺伝子産生促進剤 |
-
2017
- 2017-07-21 WO PCT/JP2017/026502 patent/WO2018016631A1/ja active Application Filing
- 2017-07-21 KR KR1020197001996A patent/KR102523796B1/ko active IP Right Grant
- 2017-07-21 CN CN201780045326.8A patent/CN109475580A/zh active Pending
- 2017-07-21 JP JP2018528897A patent/JP6996038B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01207242A (ja) * | 1988-02-15 | 1989-08-21 | Tsumura & Co | 副作用軽減剤 |
JPH02300131A (ja) * | 1989-05-15 | 1990-12-12 | Tsumura & Co | 発癌抑制剤 |
JP2014208697A (ja) * | 2001-10-31 | 2014-11-06 | 有限会社大長企画 | 動物用皮膚用剤 |
JP2007001909A (ja) * | 2005-06-22 | 2007-01-11 | Kanebo Home Products Kk | 植物抽出物の選択方法 |
CN101214057A (zh) * | 2007-01-04 | 2008-07-09 | 肖社生 | 一种养颜护肤品 |
CN101099843A (zh) * | 2007-07-18 | 2008-01-09 | 广州中医药大学 | 一种延缓皮肤衰老的中药组合物 |
JP2015501647A (ja) * | 2011-12-29 | 2015-01-19 | シャンドン ドンア アジャオ カンパニー リミテッドShandongdong−E E−Jiao Co., Ltd. | 活性小分子阿膠混合物、並びに、その調製方法及び用途 |
JP2016536344A (ja) * | 2013-09-25 | 2016-11-24 | シャンドン ドンア アジャオ カンパニー リミテッドShandong Dong−E E−Jiao Co., Ltd. | 毛髪改質剤組成物の製造における阿膠又は阿膠の高付加価値加工製品の応用 |
Also Published As
Publication number | Publication date |
---|---|
CN109475580A (zh) | 2019-03-15 |
JP6996038B2 (ja) | 2022-02-04 |
KR102523796B1 (ko) | 2023-04-19 |
JPWO2018016631A1 (ja) | 2019-05-09 |
KR20190065235A (ko) | 2019-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6896689B2 (ja) | 水棲動物軟骨抽出物 | |
TWI381834B (zh) | Abnormal protein removal composition | |
US20090257965A1 (en) | Abnormal protein removing composition | |
CN110840812A (zh) | 胎体来源的外泌体在皮肤调节产品中的用途 | |
US10932477B2 (en) | Peptide and saccharide hydrolysate of cocoa beans, cosmetic compositions containing same, and cosmetic uses of same | |
TW201625212A (zh) | 含有膠原蛋白肽之組成物的苦味掩蔽方法 | |
KR20120106703A (ko) | 콜라겐 생산 촉진제, 이를 포함하는 피부외용 조성물 및 화장료 | |
JP2021176855A (ja) | プロテインl−イソアスパラギン酸メチルトランスフェラーゼ活性化用組成物 | |
US20150265658A1 (en) | Agent for activating sirtuin gene containing egg shell membrane ingredient and composition using the same | |
JP2011190217A (ja) | ヒト皮膚表皮細胞増殖促進剤、それを含む皮膚外用組成物および化粧料 | |
KR101755360B1 (ko) | 난각막 성분을 포함한 인슐린 저항성 개선제 및 그것을 이용한 조성물 | |
WO2016183789A1 (zh) | 燕窝萃取组成物及含有所述燕窝萃取组成物的食品 | |
ES2731820T3 (es) | Extracto peptídico y osídico de fruta de Schizandra y mejora de la respuesta del sistema neurosensorial cutáneo | |
WO2018016631A1 (ja) | 皮脂量増加剤およびヒアルロン酸産生促進剤 | |
US20220193147A1 (en) | Anti-aging Composition Containing Akkermansia Muciniphila as Active Ingredient and a Method for Preventing Aging Using Thereof | |
JP2012097049A (ja) | 皮膚外用用組成物 | |
JP2017132747A (ja) | AGEs産生抑制剤 | |
JP2002047193A (ja) | アレルギー性皮膚炎予防または治療用組成物 | |
KR102511527B1 (ko) | 칠엽수 추출물을 포함하는 조성물 | |
TW201641103A (zh) | 燕窩萃取組成物及含有該燕窩萃取組成物之食品 | |
JP6375100B2 (ja) | 抗老化剤、美白剤、皮膚化粧料および飲食品 | |
KR20230103020A (ko) | 탈모방지 또는 발모촉진용 조성물 | |
JP2012017270A (ja) | 生体内グリケーション抑制剤 | |
JP2010043090A (ja) | 異常蛋白質除去用組成物 | |
JP2013203731A (ja) | ヒアルロン酸産生促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17831147 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018528897 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197001996 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17831147 Country of ref document: EP Kind code of ref document: A1 |